0810010067/J591; A Randomized Phase II Trial of 177-Lu Radio-labeled Monoclonal Antibody HuJ591 (177-Lu-J591) with Ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer after Local Therapy
Brief description of study
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
Detailed description of study
This research is being done because the standard treatments for prostate cancer that has returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal therapy are not curative. The study will assess the potential of the energy given off by the radioactive compound to kill cancer cell.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Prostate Cancer,Relapsed Prostate Cancer,Prostate,Cancer,Oncology
-
Age: 18 years - 100 years
-
Gender: Male
Inclusion Criteria
Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy
Biochemical progression (rising PSA) after medical or surgical castration
High risk of systemic progression
Exclusion Criteria
Use of red blood cell or platelet transfusions within 4 weeks of treatment
Use of hematopoietic growth factors within 4 weeks of treatment
Active serious infection
History of deep vein thrombosis and/or pulmonary embolus within 3 months of study entry
Known history of HIV.
Currently active other malignancy other than non-melanoma skin cancer.
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or